270

Bioinformatics of the Brain

[69] M. Figura, E. Sitkiewicz, B. Świderska, et al., “Proteomic profile of saliva

in parkinson’s disease patients: A proof of concept study,” Brain Sciences,

vol. 11, no. 5, p. 661, 2021.

[70] M. Boerger, S. Funke, A. Leha, et al., “Proteomic analysis of tear fluid

reveals disease-specific patterns in patients with parkinson’s disease–a

pilot study,” Parkinsonism & related disorders, vol. 63, pp. 3–9, 2019.

[71] M. Lualdi, M. Ronci, M. Zilocchi, et al., “Exploring the mitochondrial

degradome by the tails proteomics approach in a cellular model of parkin-

son’s disease,” Frontiers in Aging Neuroscience, vol. 11, p. 195, 2019.

[72] G. Costain and A. S. Bassett, “Clinical applications of schizophrenia ge-

netics: genetic diagnosis, risk, and counseling in the molecular era,” The

application of clinical genetics, pp. 1–18, 2012.

[73] J. E. Rodrigues, A. Martinho, C. Santa, et al., “Systematic review and

meta-analysis of mass spectrometry proteomics applied to human periph-

eral fluids to assess potential biomarkers of schizophrenia,” International

Journal of Molecular Sciences, vol. 23, no. 9, p. 4917, 2022.

[74] G. Reis-de Oliveira, G. Zuccoli, M. Fioramonte, et al., “Digging deeper

in the proteome of different regions from schizophrenia brains,” Journal

of proteomics, vol. 223, p. 103814, 2020.

[75] E. Velasquez, F. C. Nogueira, I. Velasquez, et al., “Synaptosomal pro-

teome of the orbitofrontal cortex from schizophrenia patients using quan-

titative label-free and itraq-based shotgun proteomics,” Journal of pro-

teome research, vol. 16, no. 12, pp. 4481–4494, 2017.

[76] M. L. MacDonald, M. Garver, J. Newman, et al., “Synaptic proteome

alterations in the primary auditory cortex of individuals with schizophre-

nia,” JAMA psychiatry, vol. 77, no. 1, pp. 86–95, 2020.

[77] V. M. Saia-Cereda, J. S. Cassoli, A. Schmitt, et al., “Differential proteome

and phosphoproteome may impact cell signaling in the corpus callosum of

schizophrenia patients,” Schizophrenia Research, vol. 177, no. 1-3, pp. 70–

77, 2016.

[78] M. Oraki Kohshour, N. R. Kannaiyan, A. J. Falk, et al., “Comparative

serum proteomic analysis of a selected protein panel in individuals with

schizophrenia and bipolar disorder and the impact of genetic risk burden

on serum proteomic profiles,” Translational Psychiatry, vol. 12, no. 1,

p. 471, 2022.

[79] L. Smirnova, A. Seregin, I. Boksha, et al., “The difference in serum pro-

teomes in schizophrenia and bipolar disorder,” BMC genomics, vol. 20,

no. 7, pp. 1–14, 2019.